386 related articles for article (PubMed ID: 28938087)
1. Emerging Opportunities for Target Discovery in Rare Cancers.
Sharifnia T; Hong AL; Painter CA; Boehm JS
Cell Chem Biol; 2017 Sep; 24(9):1075-1091. PubMed ID: 28938087
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery.
Luo J
Trends Cancer; 2016 Jun; 2(6):313-324. PubMed ID: 28603775
[TBL] [Abstract][Full Text] [Related]
3. Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
Nguyen TTT; Tamai M; Harama D; Kagami K; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Int J Hematol; 2022 Oct; 116(4):534-543. PubMed ID: 35524023
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
5. CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer.
Tsujino T; Komura K; Inamoto T; Azuma H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884583
[TBL] [Abstract][Full Text] [Related]
6. Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.
Guo X; Chitale P; Sanjana NE
Adv Exp Med Biol; 2017; 1016():123-145. PubMed ID: 29130157
[TBL] [Abstract][Full Text] [Related]
7. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F
Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961
[TBL] [Abstract][Full Text] [Related]
8. T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
Tamai M; Inukai T; Kojika S; Abe M; Kagami K; Harama D; Shinohara T; Watanabe A; Oshiro H; Akahane K; Goi K; Sugihara E; Nakada S; Sugita K
Sci Rep; 2018 Jul; 8(1):9966. PubMed ID: 29967475
[TBL] [Abstract][Full Text] [Related]
9. High-throughput functional genomics using CRISPR-Cas9.
Shalem O; Sanjana NE; Zhang F
Nat Rev Genet; 2015 May; 16(5):299-311. PubMed ID: 25854182
[TBL] [Abstract][Full Text] [Related]
10. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
11. A first-generation pediatric cancer dependency map.
Dharia NV; Kugener G; Guenther LM; Malone CF; Durbin AD; Hong AL; Howard TP; Bandopadhayay P; Wechsler CS; Fung I; Warren AC; Dempster JM; Krill-Burger JM; Paolella BR; Moh P; Jha N; Tang A; Montgomery P; Boehm JS; Hahn WC; Roberts CWM; McFarland JM; Tsherniak A; Golub TR; Vazquez F; Stegmaier K
Nat Genet; 2021 Apr; 53(4):529-538. PubMed ID: 33753930
[TBL] [Abstract][Full Text] [Related]
12. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.
Weeber F; Ooft SN; Dijkstra KK; Voest EE
Cell Chem Biol; 2017 Sep; 24(9):1092-1100. PubMed ID: 28757181
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.
Pacini C; Duncan E; Gonçalves E; Gilbert J; Bhosle S; Horswell S; Karakoc E; Lightfoot H; Curry E; Muyas F; Bouaboula M; Pedamallu CS; Cortes-Ciriano I; Behan FM; Zalmas LP; Barthorpe A; Francies H; Rowley S; Pollard J; Beltrao P; Parts L; Iorio F; Garnett MJ
Cancer Cell; 2024 Feb; 42(2):301-316.e9. PubMed ID: 38215750
[TBL] [Abstract][Full Text] [Related]
14. A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way?
Taylor J; Woodcock S
J Biomol Screen; 2015 Sep; 20(8):1040-51. PubMed ID: 26048892
[TBL] [Abstract][Full Text] [Related]
15. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
[TBL] [Abstract][Full Text] [Related]
16. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches to map small molecule-target interactions.
Kapoor S; Waldmann H; Ziegler S
Bioorg Med Chem; 2016 Aug; 24(15):3232-45. PubMed ID: 27240466
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
19. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.
Krill-Burger JM; Dempster JM; Borah AA; Paolella BR; Root DE; Golub TR; Boehm JS; Hahn WC; McFarland JM; Vazquez F; Tsherniak A
Genome Biol; 2023 Aug; 24(1):192. PubMed ID: 37612728
[TBL] [Abstract][Full Text] [Related]
20. [CRISPR/Cas9-mediated microRNA-21 knockout increased imatinib sensitivity in chronic myeloid leukemia cells].
Zhang Y; Wang LY; Li JZ; Jiang PF; Hu JD; Chen BY
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):243-249. PubMed ID: 33910311
[No Abstract] [Full Text] [Related]
[Next] [New Search]
